Cargando…
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
SIMPLE SUMMARY: PARPi are approved as monotherapy agents and under advanced clinical investigation as a combination therapy for the treatment of cancer. We demonstrate for the first time that five of the approved PARPi vary in their ability to suppress cellular PARP activity after drug removal. Ruca...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688250/ https://www.ncbi.nlm.nih.gov/pubmed/36428653 http://dx.doi.org/10.3390/cancers14225559 |